Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease
Significantly Improved PK Characteristics Result in: Higher Active Enzyme Quantities, Induced Immune Tolerance Meaningful Clinical Benefit Demonstrated Across All Key Disease Parameters Reversal in eGFR Slope Achieved Suggesting Improvement in Kidney …